This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments,...
Among 46 patients, nearly all seroconverted after second shot.
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
“In a year of selective type and screen, we saw a 51% reduction in costs related to type and screen, and a 38% reduction in overall transfusion-...
Clinical Topics & News
HLH is a rare and deadly disease increasingly more present in adults, but following treatment protocol may yield favorable results.